Skip to main content

Table 2 Prescription of anti-rheumatic therapy among patients with different levels of education

From: Higher education is associated with a better rheumatoid arthritis outcome concerning for pain and function but not disease activity: results from the EIRA cohort and Swedish rheumatology register

Treatment Without degree, number (%) With degree, number (%) Crude p values, from Chi square test Adjusted p values*
Treatment initiated at the diagnosis (baseline)  
 DMARDs 2004 (86.8) 606 (85.2) 0.30 0.44
 NSAIDs 1153 (49.9) 384 (54.0) 0.06 0.10
 Cortisone 946 (41.0) 276 (38.8) 0.32 0.69
 Biologics 145 (6.3) 32 (4.5) 0.08 0.08
3-month visit  
 DMARDs 1642 (90.7) 518 (89.8) 0.52 0.59
 NSAIDs 699 (38.6) 241 (41.8) 0.17 0.10
 Cortisone 736 (40.6) 242 (41.9) 0.58 0.47
 Biologics 186 (10.3) 52 (9.0) 0.38 0.27
6-month visit  
 DMARDs 1435 (90.4) 409 (90.3) 0.93 0.56
 NSAIDs 558 (35.2) 165 (36.4) 0.62 0.26
 Cortisone 606 (38.2) 173 (38.2) 0.99 0.89
 Biologics 203 (12.8) 56 (12.4) 0.81 0.42
1-year visit  
 DMARDs 1807 (87.7) 553 (87.5) 0.91 0.33
 NSAIDs 660 (32.0) 190 (30.1) 0.35 0.82
 Cortisone 711 (34.5) 223 (35.3) 0.72 0.86
 Biologics 357 (17.3) 120 (19.0) 0.34 0.65
  1. *P values were adjusted for age at diagnosis, gender, alcohol assumption, pack-years of smoking, body mass index, and baseline outcome values. DMARDs disease-modifying anti-rheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs